Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders
The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.
Sana Biotechnology raises more than $700M for cell, gene therapy efforts
The co-founders of the company include Hans Bishop, who founded Juno Therapeutics - one of the earliest commercial developers of CAR-T cell therapy technology - in 2013.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Venture capital firm Omega Funds closes $438M Fund VI
In a phone interview, Managing Director Otello Stampacchia noted that the firm has already invested some money from Fund VI in biopharma startups.
Kronos Bio bags $105M in Series A round for platform technology
The company, led by a Gilead Sciences veteran, plans to use the platform to find drugs that go after "undruggable" targets.
Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
Prevail Therapeutics raises $50M for gene therapy in Parkinson’s, other neurodegenerative disorders
The company hopes the funding will move it toward the clinic. Active clinical programs of gene therapies in Parkinson's include efforts by Voyager Therapeutics and a university in Japan.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Single-letter gene editing startup Beam Therapeutics raises $135M Series B round
The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.
Morphic raises $80M in Series B round to fund oral integrin inhibitor development
The company hopes to start IND-enabling studies and clinical trials next year of orally available drugs in a class currently dominated by injected monoclonal antibodies.
Q&A with founder of Omega Funds, the reclusive VC firm behind Juno, Gossamer Bio, and Editas
Having co-led the $100 million Series A transaction in Gossamer Bio, the founder of Omega Funds believes its time for the fund to come out of its protective shell.
Is too much money being invested in oncology?
Oncology startups are raking in lion's share of early-stage capital and recent M&A's have also been heavily weighted toward oncology. Is too much capital going to overcome cancer?
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.